Showing 1341-1350 of 1690 results for "".
- Clinical Implications of Pimavanserin Association With Mortality in Parkinson Disease Psychosishttps://practicalneurology.com/news/clinical-implications-of-pimavanserin-association-with-mortality-in-parkinson-disease-psychosis/2469708/It has been suggested that use of pimavanserin for the treatment of Parkinson disease (PD) psychosis symptoms is associated with higher mortality rates. The FDA found these rates unsimilar to that seen with other atypical antipsychotics, and both carry a black-box warning as a result. This has be
- Poor Sleep Associated With Long-Term Cognitive Decline in Hispanic/Latinxhttps://practicalneurology.com/news/poor-sleep-associated-with-long-term-cognitive-decline-in-hispaniclatinx/2469602/According to research led by University of Miami Miller School of Medicine neurology faculty, poor sleep is associated with the risk of long-term cognitive decline in Hispanic/Latinx adults. A paper published online on May 25, 2021 in Alzheimer & Dementia reported the risk was
- Higher Risks for Alzheimer Disease Associated With Living in Poorer Areashttps://practicalneurology.com/news/higher-risks-for-alzheimer-disease-associated-with-living-in-poorer-areas/2469553/According to a study in Neurology, individuals living in areas with higher poverty levels and fewer opportunities had more atrophy on brain scans and showed faster decline on cognitive tests, both associated with risk of Alzheimer disease (AD). In this longitudinal study, individuals with a
- Using Cannabis for Migraine Relief May Be Associated With Medication-Adaptation Headachehttps://practicalneurology.com/news/using-cannabis-for-migraine-relief-may-be-associated-with-medication-adaptation-headache/2469519/A preliminary study found that using cannabis for relief from migraine headache may be associated with medication-adaptation headache (MAH; also called medication-overuse headache). The records of 368 people who had chronic migraine (15 or more headache days per month) for at leas
- Muscular Dystrophy Association Launches Data Reporting and Visualization Platform for Neuromuscular Diseasehttps://practicalneurology.com/news/muscular-dystrophy-association-launches-data-reporting-and-visualization-platform-for-neuromuscular-disease/2469411/The Muscular Dystrophy Association (MDA) has announced the availability of its new data sharing platform, the neuromuscular observational research (MOVR) visualization and reporting platform (VRP). MOVR-VRP represents a milestone in advancing neuromuscular disease research and improving patient c
- Anticholinergics May be Associated With Increased Risk of Mild Cognitive Impairmenthttps://practicalneurology.com/news/anticholinergics-may-be-associated-with-increased-risk-of-mild-cognitive-impairment/2469368/According to a study published in Neurology, an increase of risk developing mild cognitive impairment (MCI) may be associated with use of anticholinergic medications. The cognitive decline is shown in individuals with genetic conditions for Alzheimer disease (AD) or markers of this condition,&nbs
- FDA Approves ppCBD to Treat Seizures Associated with Tuberous Sclerosis Complexhttps://practicalneurology.com/news/fda-approves-ppcbd-to-treat-seizures-associated-with-tuberous-sclerosis-complex/2469341/The Food and Drug Administration (FDA) has approved prescription pharmaceutical cannabidiol (ppCBD) (Epidiolex; GW Pharmaceuticals, Carlsbad, CA) oral solution to treat seizures associated with tuberous sclerosis complex (TSC) in patients age 1 year or more. Along with this new indication, the ag
- FDA Approves Fenfluramine for Treatment of Seizures Associated with Dravet Syndromehttps://practicalneurology.com/news/fda-approves-fenfluramine-for-treatment-of-seizures-associated-with-dravet-syndrome/2469308/The Food and Drug Administration (FDA) has approved fenfluramine (Fintepla; Zogenix, Emeryville, CA), oral solution for treatment of seizures associated with Dravet syndrome (DS) in individuals age 2 years or more. Fenfluramine will be launched through a restricted distribution program, called th
- May 1 Facebook Live Session on ALS Sponsored by Muscular Dystrophy Associationhttps://practicalneurology.com/news/may-1-facebook-live-session-on-als-sponsored-by-muscular-dystrophy-association/2469236/To mark the beginning of amyotrophic lateral sclerosis (ALS) awareness month, the Muscular Dystrophy Association (ALS) is sponsoring a special virtual conversation on Facebook Live about best practices and precautions for people with ALS during the COVID-19 pandemic. The Facebook Live event
- Muscular Dystrophy Association Launches Survey to Prioritize Needs During Pandemichttps://practicalneurology.com/news/muscular-dystrophy-association-launches-survey-to-prioritize-needs-during-pandemic/2469231/Even during the COVID-19 pandemic, efforts are being made to best serve the neuromuscular community. A survey was launched by the Muscular Dystrophy Association for the neuromuscular disability community, including caregivers. The survey has 10 questions and designed to identify the most pressing